Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891189583> ?p ?o ?g. }
Showing items 1 to 86 of
86
with 100 items per page.
- W2891189583 abstract "TPS3112 Background: Bispecific antibodies to facilitate T-cell directed cytotoxicity (TDCC) is a proven therapy strategy in cancer. ERY974 is a humanized IgG4 bispecific antibody designed to simultaneously bind to cytotoxic T-cell CD3 receptors and GPC3 (a glycoprotein expressed on cell surface of several tumors) to elicit T-cell activation and TDCC. The objectives of this multi-country, phase 1 study of ERY974 is to determine the maximum tolerated dose (MTD) and to perform a preliminary assessment of anti-tumor activity in patients with solid tumors expressing GPC3. Methods: ERY974 is dosed IV weekly. All patients receive premedication with dexamethasone (DEX) prior to 1 st and 2 nd ERY974 dose. DE uses an accelerated titration design (ATD), then a modified continual reassessment method (mCRM) described by one-parameter logistic model, to determine MTD, where DLT occurrence rate is 0.25. Combining ATD and mCRM is to permit rapid dose escalation whilst minimizing patient numbers exposed to sub-therapeutic doses, and to accurately determine MTD. Once grade 2 (G2) cytokine release syndrome (CRS) is observed, DEX is increased. If ≥G2 CRS is again observed, then at all subsequent doses the 1 st dose of ERY974 is fixed at the last dose level when < G2 CRS was not seen, DE proceeds with the 2 nd dose. ATD commences with n = 1, increasing to n = 3 once drug-related ≥G2 toxicity is seen. mCRM starts after 1 st dose limiting toxicity (DLT), with the modifications of at least 3 patients required to dose escalate and up to 1.5x increment to minimize risk of toxicity. CE has 3 arms: GPC3+ gastric/gastroesophageal junction adenocarcinoma; GPC3+ squamous esophageal cancer; and other GPC3+ tumors. A 2-stage design is used to allow CE to stop early for futility. Subjects are adults with histologically confirmed, measurable malignant solid tumors and/or metastatic disease not amenable to standard therapy, and life expectancy ≥3 months. Patients with > 1cm or > 1 brain metastasis, current/previous interstitial lung disease, and acute/chronic infection are excluded. 3 cohorts have been completed without DLT. Cohort 4 began in January 2017. Clinical trial information: NCT02748837." @default.
- W2891189583 created "2018-09-27" @default.
- W2891189583 creator A5003911767 @default.
- W2891189583 creator A5005498839 @default.
- W2891189583 creator A5017212730 @default.
- W2891189583 creator A5023373026 @default.
- W2891189583 creator A5063374954 @default.
- W2891189583 creator A5076192933 @default.
- W2891189583 creator A5077039190 @default.
- W2891189583 creator A5080687439 @default.
- W2891189583 creator A5082208570 @default.
- W2891189583 creator A5088442225 @default.
- W2891189583 date "2017-05-20" @default.
- W2891189583 modified "2023-09-27" @default.
- W2891189583 title "A phase I dose escalation (DE) and cohort expansion (CE) study of ERY974, an anti-glypican 3 (GPC3)/CD3 bispecific antibody, in patients with advanced solid tumors." @default.
- W2891189583 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.tps3112" @default.
- W2891189583 hasPublicationYear "2017" @default.
- W2891189583 type Work @default.
- W2891189583 sameAs 2891189583 @default.
- W2891189583 citedByCount "0" @default.
- W2891189583 crossrefType "journal-article" @default.
- W2891189583 hasAuthorship W2891189583A5003911767 @default.
- W2891189583 hasAuthorship W2891189583A5005498839 @default.
- W2891189583 hasAuthorship W2891189583A5017212730 @default.
- W2891189583 hasAuthorship W2891189583A5023373026 @default.
- W2891189583 hasAuthorship W2891189583A5063374954 @default.
- W2891189583 hasAuthorship W2891189583A5076192933 @default.
- W2891189583 hasAuthorship W2891189583A5077039190 @default.
- W2891189583 hasAuthorship W2891189583A5080687439 @default.
- W2891189583 hasAuthorship W2891189583A5082208570 @default.
- W2891189583 hasAuthorship W2891189583A5088442225 @default.
- W2891189583 hasConcept C114684123 @default.
- W2891189583 hasConcept C121608353 @default.
- W2891189583 hasConcept C126322002 @default.
- W2891189583 hasConcept C147483822 @default.
- W2891189583 hasConcept C159654299 @default.
- W2891189583 hasConcept C167672396 @default.
- W2891189583 hasConcept C203014093 @default.
- W2891189583 hasConcept C2777701055 @default.
- W2891189583 hasConcept C2778019345 @default.
- W2891189583 hasConcept C2779742787 @default.
- W2891189583 hasConcept C3020495827 @default.
- W2891189583 hasConcept C502942594 @default.
- W2891189583 hasConcept C542903549 @default.
- W2891189583 hasConcept C71924100 @default.
- W2891189583 hasConceptScore W2891189583C114684123 @default.
- W2891189583 hasConceptScore W2891189583C121608353 @default.
- W2891189583 hasConceptScore W2891189583C126322002 @default.
- W2891189583 hasConceptScore W2891189583C147483822 @default.
- W2891189583 hasConceptScore W2891189583C159654299 @default.
- W2891189583 hasConceptScore W2891189583C167672396 @default.
- W2891189583 hasConceptScore W2891189583C203014093 @default.
- W2891189583 hasConceptScore W2891189583C2777701055 @default.
- W2891189583 hasConceptScore W2891189583C2778019345 @default.
- W2891189583 hasConceptScore W2891189583C2779742787 @default.
- W2891189583 hasConceptScore W2891189583C3020495827 @default.
- W2891189583 hasConceptScore W2891189583C502942594 @default.
- W2891189583 hasConceptScore W2891189583C542903549 @default.
- W2891189583 hasConceptScore W2891189583C71924100 @default.
- W2891189583 hasLocation W28911895831 @default.
- W2891189583 hasOpenAccess W2891189583 @default.
- W2891189583 hasPrimaryLocation W28911895831 @default.
- W2891189583 hasRelatedWork W1978694012 @default.
- W2891189583 hasRelatedWork W2063255053 @default.
- W2891189583 hasRelatedWork W2082401167 @default.
- W2891189583 hasRelatedWork W2376876105 @default.
- W2891189583 hasRelatedWork W2384847093 @default.
- W2891189583 hasRelatedWork W2600027524 @default.
- W2891189583 hasRelatedWork W2600695631 @default.
- W2891189583 hasRelatedWork W3007061771 @default.
- W2891189583 hasRelatedWork W3010224281 @default.
- W2891189583 hasRelatedWork W3031490660 @default.
- W2891189583 hasRelatedWork W3046798230 @default.
- W2891189583 hasRelatedWork W3168407158 @default.
- W2891189583 hasRelatedWork W3169385529 @default.
- W2891189583 hasRelatedWork W3172005024 @default.
- W2891189583 hasRelatedWork W3172598012 @default.
- W2891189583 hasRelatedWork W3209244677 @default.
- W2891189583 hasRelatedWork W3214196676 @default.
- W2891189583 hasRelatedWork W2906936995 @default.
- W2891189583 hasRelatedWork W2987797326 @default.
- W2891189583 hasRelatedWork W3182958822 @default.
- W2891189583 isParatext "false" @default.
- W2891189583 isRetracted "false" @default.
- W2891189583 magId "2891189583" @default.
- W2891189583 workType "article" @default.